Most active New York Stock Exchange-traded stocks
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Tue Aug 12, 5:11PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Business Highlights
By The Associated Press - AP - Tue Aug 12, 5:05PM CDT
___
UBS AG Contemplates $4.5B Bond Offerings in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:05PM CDT
As per Bloomberg, the Swiss major UBS AG (UBS) is planning corporate bond offerings in the U.S. The bank will be issuing $4.5 billion worth of bonds.
Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica(R) Studies Conducted in China
Business Wire - Tue Aug 12, 4:02PM CDT
Pfizer Inc. (NYSE
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
PR Newswire Europe - Tue Aug 12, 12:50PM CDT
DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" [http://www.researchandmarkets.com/research/kpr76z/biological_drugs] report to their offering.
Midday Glance: Pharmaceuticals companies
AP - Tue Aug 12, 12:48PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
5 Things Pfizer Inc.'s Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 12, 12:27PM CDT
Big pharma giant Pfizer reported its second quarter earnings results two weeks ago, reminding shareholders that the patent cliff is very real, and that its operations are going through a sizable shift. For the quarter, Pfizer reported that...
Early Glance: Pharmaceuticals companies
AP - Tue Aug 12, 11:14AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Pfizer, 23andMe team up to study bowel disease
By MATTHEW PERRONE - AP - Tue Aug 12, 10:24AM CDT
WASHINGTON (AP) — Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.
Study Links Viagra(R) to Skin Cancer
Marketwire - Tue Aug 12, 10:20AM CDT
A recent study published in The Journal of the American Medical Association found that men who take Viagra® have an almost 84 percent greater risk of developing melanoma, one of the most aggressive forms of skin cancer. The study analyzed data from more than 25,000 men and controlled for factors such as sun exposure and family medical history.
Entia Biosciences' Supplements Could Prevent Dementia
ACCESSWIRE - Tue Aug 12, 8:55AM CDT
WHITEFISH, MT / ACCESSWIRE / August 12, 2014 / Vitamin D deficiency has been associated with a number of conditions, ranging from cardiovascular disease to certain types of cancers, according to WebMD. On the other side of the coin, research suggests that vitamin D could play a role in the prevention and treatment of diabetes, hypertension, glucose intolerance, multiple sclerosis, and a number of other serious medical conditions.
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
23andMe Announces Agreement with Pfizer Inc. to Research Genetics of Ulcerative Colitis and Crohn's Disease
PR Newswire - Tue Aug 12, 8:00AM CDT
23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.
Global Macular Edema Market 2014-2018 with Bayer AG, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Aug 12, 6:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6chxqf/global_macular) has announced the addition of the "Global Macular Edema Market 2014-2018" report to their offering. The Global Macular Edema market will grow at a CAGR of 9.1% over the period 2014-2018. NICE issues and updates technology appraisals and clinical guidelines to recommend appropriate and effective treatments for different diseases. It plays a role in increasing drug sales. In January 2013, NICE recommended Lucentis for the treatment of DME. This recommendation superseded the November 2011 guidance, which concluded that recommending Lucentis was not effective utilization of NHS resources. Lucentis has also been recommended for the treatment of vision impairment as a result of macular edema associated with RVO According to the report, the Global Macular Edema market is driven by several factors, of which the increase in the patient population is one of the major drivers. Eye diseases such as DR, retinal dystrophies, AMD, inflammatory conditions such as uveitis, and RVO cause macular edema. The increase in the incidence and prevalence of ophthalmological conditions such as AMD and DR is expected to increase the patient population with macular edema during the forecast period. Further, the report states that although the Global Macular Edema market has several drivers, the growth of the market is curtailed by some serious challenges. One of the main challenges is increased use of off-label drugs. Use of off-label drugs increases the market competition for approved branded drugs. Some of the off-label drugs for the treatment of macular edema are bevacizumab, topical NSAIDs, and drugs such as acetazolamide. The report also includes a discussion of the other vendors operating in this market. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Alcon Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - iCo Therapeutics Inc. - Pfizer Inc. - Santen Pharmaceutical Co. Ltd. For more information visit http://www.researchandmarkets.com/research/6c...al_macular
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
AIDS activist takes up a new fight: defending FDA
By MATTHEW PERRONE - AP - Mon Aug 11, 3:49PM CDT
WASHINGTON (AP) — As an AIDS activist in the early 1990s, Gregg Gonsalves traveled to Washington to challenge the Food and Drug Administration.
Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
PR Newswire - Mon Aug 11, 6:00AM CDT
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF® (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.